Stockscreener 앱 받기
13.35
6.71%
0.84
전일 마감가:
$12.51
열려 있는:
$12.63
하루 거래량:
2.10M
Relative Volume:
1.09
시가총액:
$1.90B
수익:
순이익/손실:
$-45.61M
주가수익비율:
-41.27
EPS:
-0.3235
순현금흐름:
$-45.40M
1주 성능:
+4.54%
1개월 성능:
-7.29%
6개월 성능:
-3.54%
1년 성능:
+26.78%
1일 변동 폭
$0.00
$0.00
1주일 범위
$12.34
$13.45
52주 변동 폭
$9.82
$20.22
트레비 테라퓨틱스 Stock (TRVI) Company Profile
명칭
Trevi Therapeutics Inc
전화
203-304-2499
주소
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
13.35 | 1.90B | 0 | -45.61M | -45.40M | -0.3235 |
VRTX
Vertex Pharmaceuticals Inc
|
521.03 | 132.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
816.10 | 84.02B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
207.97 | 83.03B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
882.48 | 55.50B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
366.06 | 41.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-07-21 | 개시 | BMO Capital Markets | Outperform |
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-08-21 | 개시 | Morgan Stanley | Overweight |
| 2025-07-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-03-10 | 재확인 | Needham | Buy |
| 2025-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-30 | 개시 | Raymond James | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-12 | 개시 | B. Riley Securities | Buy |
| 2022-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | BMO Capital Markets | Outperform |
| 2019-06-03 | 개시 | Needham | Buy |
| 2019-06-03 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | Stifel | Buy |
모두보기
트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스
Oppenheimer reiterates Trevi Therapeutics stock rating ahead of trial update - Investing.com
Trevi Therapeutics (TRVI) director sells 39,473 shares under trading plan - Stock Titan
Trevi Therapeutics stock trades in a data vacuum as Haduvio moves toward Phase 3 - AD HOC NEWS
Trevi Therapeutics Insider Sold Shares Worth $595,806, According to a Recent SEC Filing - Yahoo Finance
Trevi Therapeutics stock trades in a data vacuum as Haduvio moves toward Phase 3 - ad-hoc-news.de
Director at Trevi Therapeutics (NASDAQ: TRVI) plans share sale after option exercise - Stock Titan
Trevi Therapeutics at cantor global healthcare conference: central cough bet By Investing.com - Investing.com Canada
Trevi Therapeutics at cantor global healthcare conference: central cough bet By Investing.com - Investing.com UK
BMO initiates coverage on Trevi Therapeutics at $36 - scanx.trade
Trevi Therapeutics (TRVI) Edges Lower 1.07% as Shares Consolidate Between Key Support and ResistanceETF Outflow Streak - siam.in
Trevi Therapeutics (TRVI) Edges Lower 1.07% as Shares Consolidate Between Key Support and ResistanceTWAP Entry - dars.gov.et
Trevi Therapeutics (TRVI) Stock Trades At A Premium To Fair Value - Yahoo Finance
BEAM Stock Price and Chart — NASDAQ:BEAM - TradingView
Trevi Therapeutics Inc (TRVI) Peer Comparison – Compare with Others - Value Research
Trevi Therapeutics to Present at Multiple Healthcare and IPF Conferences in September 2026 - Quiver Quantitative
Trevi Therapeutics to Participate in Upcoming September Conferences - Yahoo Finance
Trevi Therapeutics Inc (TRVI) Key Financial Ratios – Valuation, Profitability & More - Value Research
EX-99.1 - SEC.gov
Trevi Therapeutics Inc (TRVI) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 - GlobeNewswire
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI) - Seeking Alpha
$Trevi Therapeutics (TRVI.US)$ lets punch through that BOLL band - Moomoo
Walleye Capital LLC Purchases Shares of 241,987 Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Stock Price Forecast. Should You Buy TRVI? - StockInvest.us
TRVI Maintained by Jones Trading -- Price Target Raised to $28.0 - GuruFocus
JonesTrading Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock - MarketBeat
Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)? - simplywall.st
Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)? - simplywall.st
Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)? - simplywall.st
Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)? - simplywall.st
HC Wainwright Issues Pessimistic Estimate for TRVI Earnings - MarketBeat
Sei Investments Co. Has $933,000 Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
What is HC Wainwright's Forecast for TRVI FY2030 Earnings? - MarketBeat
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Trevi Therapeutics (TRVI) Short Interest & Short Float | Updated Aug 2026 $TRVI - MarketBeat
Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23 - Moomoo
1,525,314 Shares in Trevi Therapeutics, Inc. $TRVI Acquired by Assenagon Asset Management S.A. - MarketBeat
Companies Like Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Invest In Growth - moomoo.com
A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $23 to $40 - Moomoo
Raymond James Sticks to Its Buy Rating for Trevi Therapeutics (TRVI) - The Globe and Mail
Trevi Therapeutics (TRVI) Receives a New Rating from B. Riley Securities - The Globe and Mail
Q2 2026 Trevi Therapeutics Inc Earnings Call Transcript - GuruFocus
Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $25 - Moomoo
Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $23 - Moomoo
Trevi Therapeutics (NASDAQ:TRVI) Announces Earnings Results, Hits Estimates - marketbeat.com
Trevi Therapeutics Q2 Earnings Call Highlights - MarketBeat
Trevi Therapeutics Q2 Earnings Call Highlights - TradingView
Trevi Therapeutics, Inc. Stock 12‑Month Price Target Raised to $29.17, Implies 58% Upside - TradingView
Trevi Therapeutics Inc (TRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TRVI Maintains Rating by Oppenheimer -- Price Target Raised to $25.00 - GuruFocus
트레비 테라퓨틱스 (TRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
트레비 테라퓨틱스 주식 (TRVI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Heffernan Michael Thomas | Director |
Sep 15 '26 |
Sale |
15.09 |
39,473 |
595,806 |
6,351 |
| MICHAEL HEFFERNAN | Director |
Sep 15 '26 |
Proposed Sale |
15.89 |
39,473 |
627,226 |
0 |
| Galletta Christopher | See Remarks |
Dec 02 '25 |
Option Exercise |
0.51 |
4,225 |
2,159 |
26,095 |
| Delfini Lisa | Officer |
Oct 07 '25 |
Proposed Sale |
9.50 |
108,650 |
1,032,175 |
0 |
| Delfini Lisa | Officer |
Oct 03 '25 |
Proposed Sale |
9.67 |
40,000 |
386,716 |
0 |
4.37%
0.23%
자본화:
|
볼륨(24시간):